About
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment comprises of technologies or diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When did Boston Scientific become a publicly traded company?
- Boston Scientific went public on the NYSE in May 1992.
- What was a significant acquisition made by Boston Scientific in March 2025?
- In March 2025, Boston Scientific acquired Sonivie, an Israeli medical device company based in Rehovot, for up to $540 million. Sonivie develops intravascular ultrasound devices for treating high blood pressure.
- What was Boston Scientific's acquisition in March 2021?
- In March 2021, Boston Scientific announced its intention to acquire the surgical division of Lumenis for $1.1 billion.
- What operational change is Boston Scientific making regarding Galil Medical's activity?
- Boston Scientific is transferring Galil Medical's activity from Yokne'am to Galway, Ireland. This transfer is expected to be completed by 2028 and affects approximately 100 employees.
- When did Boston Scientific establish its presence in Israel?
- Boston Scientific has had a presence in Israel since April 2000.
- What distribution deal did Boston Scientific sign in October 2018?
- In October 2018, Boston Scientific signed a distribution deal with Israeli company Allium Medical.
- What was the outcome for Israeli investors from Boston Scientific's Rythmia acquisition?
- In October 2012, Israeli investors profited from Boston Scientific's acquisition of Rythmia.
- What is Boston Scientific's primary business focus?
- Boston Scientific Corp. develops, manufactures, and markets medical devices used in interventional medical specialties, categorized into Rhythm and Neuro, Cardiovascular, and MedSurg segments.